| 1 |
34787825 | A case of a hemodialysis patient with secondary hyperparathyroidism who was resistant to etelcalcetide treatment but not to cinacalcet hydrochloride. | 2022 May |
1 |
| 2 |
33047189 | Effect of etelcalcetide on parathyroid hormone secretion by primary hyperparathyroidism patient-derived primary parathyroid cells. | 2021 May |
4 |
| 3 |
34372813 | Bone responsiveness to parathyroid hormone is negatively associated with parathyroid hormone-lowering drug use in patients undergoing hemodialysis: a cross-sectional study. | 2021 Aug 9 |
1 |
| 4 |
32467152 | International Union of Basic and Clinical Pharmacology. CVIII. Calcium-Sensing Receptor Nomenclature, Pharmacology, and Function. | 2020 Jul |
2 |
| 5 |
28508378 | Population Pharmacokinetic and Pharmacodynamic Modeling of Etelcalcetide in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis. | 2018 Jan |
2 |
| 6 |
30009474 | Treatment of secondary hyperparathyroidism: How do cinacalcet and etelcalcetide differ? | 2018 Sep |
1 |
| 7 |
28336830 | [The Discovery, Research and Development of Etelcalcetide Hydrochloride, the World 1st Intravenous Calcimimetics.] | 2017 |
2 |
| 8 |
28615947 | Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide. | 2017 |
1 |
| 9 |
23674604 | Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients. | 2013 Aug |
3 |